[THE INVESTOR] Korea’s genomic research firm DNA Link said on Feb. 26 it has entered an agreement with US-based Twist BioScience for sales and co-development of DNA synthesis technology.
With the contract, DNA Link will offer a wide range of services including gene synthesis, cloning, cancer panel and libraries for gene editing technology CRISPR that will help hospitals, drug makers and biotech companies accelerate their research and product development efforts, the Korean company said in a statement.
It also plans to introduce Twist BioScience’s technology that uses DNA to store digital data to IT companies here.
“We are continuously expanding our business through genome analysis such as DNA data storage,” a DNA Link official said. “Based on our global sourcing experience and know-how, we will pursue partnerships with overseas companies with promising technologies.”
Founded in 2013, the US startup has attracted some US$191 million from Microsoft and others.
In September last year, Twist BioScience said it has successfully stored archival-quality audio recordings of two music performances on DNA for the first time in a collaboration with Microsoft and University of Washington.
By Park Han-na (email@example.com)